Opinion|Videos|December 22, 2023
Patient Characteristics in Real-World Study on Teclistamab
Author(s)Danai Dima, MD
Danai Dima, MD, further explores the patient characteristics in the R/R MM teclistamab real-world study.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer
2
Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma
3
c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5